Clinical Trials Browser

Phase 1 × Interventional × saracatinib × Clear all

Lymphangioleiomyomatosis

NCT00704366 2011-05-16

AZD0530 Study 21 - Phase I Study in Patients With Solid Tumours

Phase 1 Completed

18 enrolled

Other solid neoplasm

Solid Tumor

NCT00475956 2010-04-15

Safety and Tolerability Study of AZD2171 in Combination With AZD0530 in Patients With Advanced Solid Tumours

Phase 1 Completed

40 enrolled

BreastGastrointestinalGynecologicPlasma cellThoracic

Breast Neoplasms, Choriocarcinoma, Colonic Neoplasms, Liver Neoplasms, Lung Neoplasms, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Cholangiocarcinoma, Neoplasms, Plasma Cell

NCT01000896 2010-02-04

Study to Assess Safety and Tolerability of AZD0530 in Combination With Carboplatin and Paclitaxel

Phase 1 Withdrawn

27 enrolled

GynecologicThoracic

Carcinoma, Ovarian Epithelial, Carcinoma, Non-Small-Cell Lung, Neoplasms

Clinical Trials

The Tolerability of Saracatinib in Subjects With Lymphangioleiomyomatosis (LAM) (SLAM-1)

AZD0530 Study 21 - Phase I Study in Patients With Solid Tumours

Safety and Tolerability Study of AZD2171 in Combination With AZD0530 in Patients With Advanced Solid Tumours

Study to Assess Safety and Tolerability of AZD0530 in Combination With Carboplatin and Paclitaxel